Published in Current Treatment Options in Infectious Diseases
Purpose of review Hantavirus infection is an emerging zoonosis and there are two main clinical presentations, hemorrhagic fever with renal syndrome (HFRS) and Hantavirus pulmonary syndrome (HPS). Although Hantavirus infections have a worldwide distribution with a high mortality rate, a safe and effective vaccine or an antiviral drug against the Han...
Published in Current Treatment Options in Infectious Diseases
Purpose of Review Surveillance of communicable diseases is essential in all countries to prevent and control infections, to detect outbreaks and also to see the effects of interventions. The data should be reliable, and collection, analysis and feedback as well as the action based on this data should be fast. In this article, author discusses the l...
Published in Current treatment options in infectious diseases
Hepatitis C (HCV) is the most common cause of viral hepatitis in elderly individuals. This patient population previously experienced suboptimal outcomes with interferon-based regimens. Unfortunately, patients aged 65 years and older were underrepresented in phase 2 and 3 clinical trials with newer direct acting antiviral (DAA) therapies. Since the ...
Published in Current treatment options in infectious diseases
We aim to provide the readers an up-to-date knowledge of the structure, epidemiology, and transmission followed by a detailed discussion on testing, diagnostics and management of hepatitis E virus infection. We have also included a comprehensive review of hepatitis E in pregnancy. European Association for the Study of the Liver established clinical...
Published in Current treatment options in infectious diseases
At the turn of the nineteenth century, yellow fever (YF) was considered the most dangerous infectious disease with high case fatality. Subsequent, mass vaccination campaigns coupled with widespread elimination of the YF mosquito vector significantly decreased YF cases and reduced outbreaks to the tropical and subtropical forested regions of Africa ...
Published in Current treatment options in infectious diseases
There is a continuing debate regarding contact precaution (CP) usage for endemic multidrug-resistant organisms (MDROs). In this review, we examine current recommendations for CP and highlight differences in CP use between endemic and non-endemic MDROs. The discontinuation of CP had no effect on the incidence of methicillin-resistant Staphylococcus ...
Published in Current Treatment Options in Infectious Diseases
Purpose of Review Artificial intelligence (AI) offers huge potential in infection prevention and control (IPC). We explore its potential IPC benefits in epidemiology, laboratory infection diagnosis, and hand hygiene. Recent Findings AI has the potential to detect transmission events during outbreaks or predict high-risk patients, enabling developme...
Published in Current Treatment Options in Infectious Diseases
Purpose of ReviewWe reviewed the benefit of influenza vaccination in healthcare personnel (HCP), rates of vaccine coverage, and practices used to try to boost vaccine coverage among HCP.Recent FindingsInfluenza vaccination in HCP provides benefits to both HCP and patients, including reductions in patient morbidity and mortality and decreases in HCP...
Published in Current Treatment Options in Infectious Diseases
Purpose of reviewHealthcare-associated infections (HAIs) and rising antimicrobial resistance (AMR) have posed a major challenge in patient care across the globe, more so in lower-middle-income countries (LMICs). Studies have shown that implementation of an effective infection prevention and control (IPC) program reduces incidence of HAI to a large ...
Published in Current Treatment Options in Infectious Diseases
Purpose of reviewThis review illustrates relevant and current antibiotic use (AU) metrics and demonstrates their differences. The authors also highlight novel, increasingly complex AU metrics proposed for use in antibiotic stewardship research.Recent findingsMany common antibiotic use metrics (e.g., days of therapy, length of therapy) are well defi...
